Day of glory on the Stock Exchange for the title Molmed, which at the beginning of the afternoon gained 8,9%, to 0,3802 euro, after reaching a high for the day at 0,3895 euro.
To trigger the wave of purchases was the decision of the European Commission to grant the conditional placing on the market for Zalmoxis, the first immune-engineered cell therapy used in conjunction with haplo-identical hematopoietic stem cell transplantation in adult patients with leukemia and other high-risk blood cancers.
Conditional Marketing Authorization is a particular marketing authorization procedure that can be granted even in the absence of final data from pivotal Phase III studies.
This advance authorization is granted to medicinal products with a positive benefit/risk assessment, capable of addressing significant therapeutic needs, and whose availability would result in a relevant benefit to public health.
